Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antibody Therapies Vs. Omicron: Vir Stands Up But Regeneron And Lilly Fail

Regeneron Pledges Update By Early 2022

Executive Summary

New studies show Regeneron and Lilly’s leading COVID-19 antibody cocktails are ‘inactive’ against Omicron but there is better news for Vir, AstraZeneca and Adagio.

You may also be interested in...

Can Adagio’s Adintrevimab Hold Up Against Omicron BA.2?

The company will seek an EUA for the COVID-19 antibody after trial data indicated efficacy against Omicron, but studies have called into question its potency against the rapidly expanding subvariant.

US Restricts Use of GSK/Vir’s Xevudy, Deemed ‘Unlikely’ To Help Against Rising Omicron Variant

The constantly mutating SARS-CoV-2 has evaded yet another antibody therapy, but Vir and GSK hope that a higher dose of Xevudy could retain some efficacy against BA.2. 

Finance Watch: Financial Market Turmoil Ends Amicus SPAC Deal For Gene Therapy Spinout

Public Company Edition: As their stock prices plummet, Adagio reshuffles its research plan and names a new CEO, while Yumanity restructures and seeks strategic alternatives. Also, Bristol sells $6bn worth of notes, Amgen issues $750m green bond, and Inhibrx and Amryt amend and refinance debt.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts